Endothelial nitric oxide synthase gene polymorphisms and risk of diabetic nephropathy: A systematic review and meta-analysis

BMC Medical Genetics

Volumn 15, Issue 1, 2014, Pages

  Dellamea, Bruno S ^a   Pinto, Lana Catani F ^a   Leitão, Cristiane B ^a   Santos, Katia G ^b   Canani, Luis Henrique S ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE;

ALLELE; ARTICLE; CODOMINANCE; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DNA POLYMORPHISM; DOMINANT GENE; ETHNICITY; GENETIC ASSOCIATION; GENETIC MODEL; GENOTYPE; HUMAN; META ANALYSIS; PHENOTYPE; RISK; SYSTEMATIC REVIEW;

ANIMALS; DIABETIC NEPHROPATHIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NITRIC OXIDE SYNTHASE TYPE III; POLYMORPHISM, GENETIC;

EID: 84892406156     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-15-9     Document Type: Article

References (44)

1. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991, 43(2):109-142.
2. Asakimori Y, et al. T(-786)->C polymorphism of the endothelial nitric oxide synthase gene influences the progression of renal disease. Nephron 2002, 91(4):747-751. 10.1159/000065041, 12138283.
3. Bredt DS, Snyder SH. Nitric oxide: a physiologic messenger molecule. Annu Rev Biochem 1994, 63:175-195. 10.1146/annurev.bi.63.070194.001135, 7526779.
4. Tsutsui M, et al. Nitric oxide synthases and cardiovascular diseases: insights from genetically modified mice. Circ J 2009, 73(6):986-993. 10.1253/circj.CJ-09-0208, 19430166.
5. Zoccali C. The endothelium as a target in renal diseases. J Nephrol 2007, 20(Suppl 12):S39-S44.
6. Mount PF, Power DA. Nitric oxide in the kidney: functions and regulation of synthesis. Acta Physiol (Oxf) 2006, 187(4):433-446. 10.1111/j.1748-1716.2006.01582.x, 16866775.
7. Lahera V, et al. Effects of NG-nitro-L-arginine methyl ester on renal function and blood pressure. Am J Physiol 1991, 261(6 Pt 2):F1033-F1037.
8. Shultz PJ, Tolins JP. Adaptation to increased dietary salt intake in the rat. Role of endogenous nitric oxide. J Clin Invest 1993, 91(2):642-650. 10.1172/JCI116244, 287999, 7679414.
9. Liu Y, et al. T-786C polymorphism of the endothelial nitric oxide synthase gene is associated with albuminuria in the diabetes heart study. J Am Soc Nephrol 2005, 16(4):1085-1090. 10.1681/ASN.2004100817, 15743995.
10. Ezzidi I, et al. Association of endothelial nitric oxide synthase Glu298Asp, 4b/a, and -786T>C gene variants with diabetic nephropathy. J Diabetes Complications 2008, 22(5):331-338. 10.1016/j.jdiacomp.2007.11.011, 18413207.
11. Bellini MH, et al. Association of endothelial nitric oxide synthase gene intron 4 polymorphism with end-stage renal disease. Nephrology (Carlton) 2007, 12(3):289-293. 10.1111/j.1440-1797.2007.00787.x, 17498125.
12. Buraczynska M, et al. Endothelial nitric oxide synthase gene intron 4 polymorphism in patients with end-stage renal disease. Nephrol Dial Transplant 2004, 19(9):2302-2306. 10.1093/ndt/gfh077, 15299097.
13. Ksiazek P, et al. Endothelial nitric oxide synthase gene intron 4 polymorphism in type 2 diabetes mellitus. Mol Diagn 2003, 7(2):119-123.
14. Neugebauer S, Baba T, Watanabe T. Association of the nitric oxide synthase gene polymorphism with an increased risk for progression to diabetic nephropathy in type 2 diabetes. Diabetes 2000, 49(3):500-503. 10.2337/diabetes.49.3.500, 10868974.
15. Mamoulakis D, et al. Intron 4 polymorphism of the endothelial nitric oxide synthase eNOS gene and early microangiopathy in type 1 diabetes. Int J Immunogenet 2009, 36(3):153-157. 10.1111/j.1744-313X.2009.00839.x, 19490210.
16. Shestakova MV, et al. The relationship between genetic and haemodynamic factgors in diabetic nephropathy (DN): case-control study in type 1 diabetes mellitus (T1DM). Diabetes Res Clin Pract 2006, 74s:10.
17. Zanchi A, et al. Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int 2000, 57(2):405-413. 10.1046/j.1523-1755.2000.00860.x, 10652017.
18. Mollsten A, et al. The endothelial nitri oxide synthase gene and risk pf diabetic nephropathy and development of cardiovascular disease in type 1 diabetes. Mol Genet Metab 2009, 97:5.
19. Tiwari AK, et al. Oxidative stress pathway genes and chronic renal insufficiency in Asian Indians with Type 2 diabetes. J Diabetes Complications 2009, 23(2):102-111. 10.1016/j.jdiacomp.2007.10.003, 18413200.
20. Taniwaki H, et al. Relations between ACE gene and ecNOS gene polymorphisms and resistive index in type 2 diabetic patients with nephropathy. Diabetes Care 2001, 24(9):1653-1660. 10.2337/diacare.24.9.1653, 11522715.
21. Ahluwalia TS, et al. Endothelial nitric oxide synthase gene haplotypes and diabetic nephropathy among Asian Indians. Mol Cell Biochem 2008, 314(1-2):9-17.
22. El-Din Bessa SS, Hamdy SM. Impact of nitric oxide synthase Glu298Asp polymorphism on the development of end-stage renal disease in type 2 diabetic Egyptian patients. Ren Fail 2011, 33(9):878-884. 10.3109/0886022X.2011.605978, 21854353.
23. Cai H, et al. A common Glu298->Asp (894G->T) mutation at exon 7 of the endothelial nitric oxide synthase gene and vascular complications in type 2 diabetes. Diabetes Care 1998, 21(12):2195-2196. 10.2337/diacare.21.12.2195, 9839121.
24. Degen B, Schmidt S, Ritz E. A polymorphism in the gene for the endothelial nitric oxide synthase and diabetic nephropathy. Nephrol Dial Transplant 2001, 16(1):185.
25. Fujita H, et al. Lack of association between an ecNOS gene polymorphism and diabetic nephropathy in type 2 diabetic patients with proliferative diabetic retinopathy. Horm Metab Res 2000, 32(2):80-83. 10.1055/s-2007-978594, 10741691.
26. Lin S, Qu H, Qiu M. Allele A in intron 4 of ecNOS gene will not increase the risk of diabetic nephropathy in type 2 diabetes of Chinese population. Nephron 2002, 91(4):768. 10.1159/000065048, 12138290.
27. Rahimi Z, Vaisi-Raygani A, Parsian A. Concomitant presence of endothelial nitric oxide 894T and angiotensin II-converting enzyme D alleles are associated with diabetic nephropathy in a Kurdish population from Western Iran. Nephrology (Carlton) 2012, 17(2):175-181. 10.1111/j.1440-1797.2011.01533.x, 22026967.
28. Rippin JD, et al. Nitric oxide synthase gene polymorphisms and diabetic nephropathy. Diabetologia 2003, 46(3):426-428.
29. Santos KG, et al. Association of eNOS gene polymorphisms with renal disease in Caucasians with type 2 diabetes. Diabetes Res Clin Pract 2011, 91(3):353-362. 10.1016/j.diabres.2010.12.029, 21255858.
30. Shimizu T, et al. Endothelial nitric oxide synthase gene and the development of diabetic nephropathy. Diabetes Res Clin Pract 2002, 58(3):179-185. 10.1016/S0168-8227(02)00156-0, 12413777.
31. Shin Shin Y, et al. Relations between eNOS Glu298Asp polymorphism and progression of diabetic nephropathy. Diabetes Res Clin Pract 2004, 65(3):257-265. 10.1016/j.diabres.2004.01.010, 15331206.
32. Shoukry A, et al. Endothelial nitric oxide synthase gene polymorphisms and the risk of diabetic nephropathy in type 2 diabetes mellitus. Genet Test Mol Biomarkers 2012, 16(6):574-579. 10.1089/gtmb.2011.0218, 22313046.
33. Tamemoto H, Ishikawa SE, Kawakami M. Association of the Glu298Asp polymorphism of the eNOS Gene with ischemic heart disease in Japanese diabetic subjects. Diabetes Res Clin Pract 2008, 80(2):275-279. 10.1016/j.diabres.2007.12.019, 18243394.
34. Mollsten A, et al. Glu298Asp and NOS4ab polymorphisms in diabetic nephropathy. Ann Med 2006, 38(7):522-528. 10.1080/07853890600969213, 17101543.
35. Gross JL, et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005, 28(1):164-176. 10.2337/diacare.28.1.164, 15616252.
36. Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151(4):264-269. W64, 10.7326/0003-4819-151-4-200908180-00135, 19622511.
37. Liberati A, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009, 151(4):W65-W94.
38. Jorde LB, Wooding SP. Genetic variation, classification and 'race'. Nat Genet 2004, 36(11 Suppl):S28-S33.
39. Zintzaras E, Lau J. Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol 2008, 61(7):634-645. 10.1016/j.jclinepi.2007.12.011, 18538260.
40. Minelli C, et al. The choice of a genetic model in the meta-analysis of molecular association studies. Int J Epidemiol 2005, 34(6):1319-1328. 10.1093/ije/dyi169, 16115824.
41. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990, 1(1):43-46. 10.1097/00001648-199001000-00010, 2081237.
42. Bender R, Lange S. Adjusting for multiple testing-when and how?. J Clin Epidemiol 2001, 54(4):343-349. 10.1016/S0895-4356(00)00314-0, 11297884.
43. Egger M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634. 10.1136/bmj.315.7109.629, 2127453, 9310563.
44. Zintzaras E, Papathanasiou AA, Stefanidis I. Endothelial nitric oxide synthase gene polymorphisms and diabetic nephropathy: a HuGE review and meta-analysis. Genet Med 2009, 11(10):695-706. 10.1097/GIM.0b013e3181b2046b, 19773668.